skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 61 - 80 of 154,071  for All Library Resources

previous page 1 2 3 Results 4 5 next page
Refined by: subject: Cancer remove
Result Number Material Type Add to My Shelf Action Record Details and Options
61
Priorities for cancer research in low- and middle-income countries: a global perspective
Material Type:
Article
Add to My Research

Priorities for cancer research in low- and middle-income countries: a global perspective

Nature medicine, 2022-04, Vol.28 (4), p.649-657 [Peer Reviewed Journal]

2022. Springer Nature America, Inc. ;Springer Nature America, Inc. 2022. ;ISSN: 1078-8956 ;EISSN: 1546-170X ;DOI: 10.1038/s41591-022-01738-x ;PMID: 35440716

Full text available

62
Women in contemporary cancer research
Material Type:
Article
Add to My Research

Women in contemporary cancer research

International journal of cancer, 2020-09, Vol.147 (6), p.1571 [Peer Reviewed Journal]

2020 UICC. ;EISSN: 1097-0215 ;DOI: 10.1002/ijc.32938 ;PMID: 32086947

Digital Resources/Online E-Resources

63
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis
Material Type:
Article
Add to My Research

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

The Lancet (British edition), 2012-03, Vol.379 (9822), p.1214-1224 [Peer Reviewed Journal]

Elsevier Ltd ;2012 Elsevier Ltd ;2015 INIST-CNRS ;Copyright © 2012 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Mar 31-Apr 6, 2012 ;2012 Elsevier Ltd. All rights reserved. 2012 Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(12)60110-X ;PMID: 22421340 ;CODEN: LANCAO

Full text available

64
Cuts in cancer research funding due to COVID-19
Material Type:
Article
Add to My Research

Cuts in cancer research funding due to COVID-19

The lancet oncology, 2021-01, Vol.22 (1), p.e6-e6 [Peer Reviewed Journal]

2021 Elsevier Ltd ;2021. Elsevier Ltd ;2020 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(20)30749-X ;PMID: 33341123

Full text available

65
Realizing the Potential of Cancer Prevention — The Role of Implementation Science
Material Type:
Article
Add to My Research

Realizing the Potential of Cancer Prevention — The Role of Implementation Science

The New England journal of medicine, 2017-03, Vol.376 (10), p.986-990 [Peer Reviewed Journal]

Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMsb1609101 ;PMID: 28273020

Full text available

66
Reframing the "Cancer Moonshot"
Material Type:
Article
Add to My Research

Reframing the "Cancer Moonshot"

EMBO reports, 2016-12, Vol.17 (12), p.1685-1687 [Peer Reviewed Journal]

2016 The Author ;ISSN: 1469-221X ;EISSN: 1469-3178 ;DOI: 10.15252/embr.201643467 ;CODEN: ERMEAX

Full text available

67
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
Material Type:
Article
Add to My Research

Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

The lancet oncology, 2021-08, Vol.22 (8), p.1162-1174 [Peer Reviewed Journal]

2021 Elsevier Ltd ;2021. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(21)00302-8

Full text available

68
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles
Material Type:
Article
Add to My Research

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

The Lancet (British edition), 2013-05, Vol.381 (9880), p.1817-1826 [Peer Reviewed Journal]

Elsevier Ltd ;2013 Elsevier Ltd ;2014 INIST-CNRS ;Copyright © 2013 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited May 25, 2013 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(13)60313-X ;PMID: 23615461 ;CODEN: LANCAO

Full text available

69
Global post-mortem tissue donation programmes to accelerate cancer research
Material Type:
Article
Add to My Research

Global post-mortem tissue donation programmes to accelerate cancer research

Nature reviews. Cancer, 2024-05, Vol.24 (5), p.289-290 [Peer Reviewed Journal]

Springer Nature Limited 2024. ;ISSN: 1474-175X ;EISSN: 1474-1768 ;DOI: 10.1038/s41568-024-00683-w ;PMID: 38589555

Digital Resources/Online E-Resources

70
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
Material Type:
Article
Add to My Research

Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods

International journal of cancer, 2019-04, Vol.144 (8), p.1941 [Peer Reviewed Journal]

2018 UICC. ;EISSN: 1097-0215 ;DOI: 10.1002/ijc.31937 ;PMID: 30350310

Digital Resources/Online E-Resources

71
Raise standards for preclinical cancer research
Material Type:
Article
Add to My Research

Raise standards for preclinical cancer research

Nature (London), 2012-03, Vol.483 (7391), p.531-533 [Peer Reviewed Journal]

Copyright Nature Publishing Group Mar 29, 2012 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/483531a ;CODEN: NATUAS

Full text available

72
Big data in basic and translational cancer research
Material Type:
Article
Add to My Research

Big data in basic and translational cancer research

Nature reviews. Cancer, 2022-11, Vol.22 (11), p.625-639 [Peer Reviewed Journal]

This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. ;This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. ;ISSN: 1474-175X ;EISSN: 1474-1768 ;DOI: 10.1038/s41568-022-00502-0 ;PMID: 36064595

Full text available

73
Black voices in cancer research and oncology
Material Type:
Article
Add to My Research

Black voices in cancer research and oncology

Nature reviews. Cancer, 2024-04, Vol.24 (4), p.235-239 [Peer Reviewed Journal]

Springer Nature Limited 2024. ;ISSN: 1474-175X ;EISSN: 1474-1768 ;DOI: 10.1038/s41568-023-00662-7 ;PMID: 38374427

Digital Resources/Online E-Resources

74
HIV-1 viremia not suppressible by antiretroviral therapy can originate from large T cell clones producing infectious virus
Material Type:
Article
Add to My Research

HIV-1 viremia not suppressible by antiretroviral therapy can originate from large T cell clones producing infectious virus

The Journal of clinical investigation, 2020-11, Vol.130 (11), p.5847-5857 [Peer Reviewed Journal]

COPYRIGHT 2020 American Society for Clinical Investigation ;COPYRIGHT 2020 American Society for Clinical Investigation ;Copyright American Society for Clinical Investigation Nov 2020 ;2020 American Society for Clinical Investigation 2020 American Society for Clinical Investigation ;ISSN: 0021-9738 ;EISSN: 1558-8238 ;DOI: 10.1172/JCI138099 ;PMID: 33016926

Full text available

75
CRISPR in cancer biology and therapy
Material Type:
Article
Add to My Research

CRISPR in cancer biology and therapy

Nature reviews. Cancer, 2022-05, Vol.22 (5), p.259-279 [Peer Reviewed Journal]

2022. Springer Nature Limited. ;Springer Nature Limited 2022. ;ISSN: 1474-175X ;EISSN: 1474-1768 ;DOI: 10.1038/s41568-022-00441-w ;PMID: 35194172

Full text available

76
Global cancer research in the post-pandemic world
Material Type:
Article
Add to My Research

Global cancer research in the post-pandemic world

The lancet oncology, 2021-12, Vol.22 (12), p.1652-1654 [Peer Reviewed Journal]

2021 Elsevier Ltd ;2021. Elsevier Ltd ;2021 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(21)00602-1 ;PMID: 34856137

Full text available

77
Monica Bertagnolli: Director of the National Institutes of Health
Material Type:
Article
Add to My Research

Monica Bertagnolli: Director of the National Institutes of Health

The Lancet (British edition), 2024-02, Vol.403 (10427), p.605-605 [Peer Reviewed Journal]

2024 Elsevier Ltd ;2024. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(24)00262-9 ;PMID: 38368885

Full text available

78
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Material Type:
Article
Add to My Research

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

The Lancet (British edition), 2011-06, Vol.377 (9784), p.2181-2192 [Peer Reviewed Journal]

Elsevier Ltd ;2011 Elsevier Ltd ;2015 INIST-CNRS ;Copyright © 2011 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jun 25-Jul 1, 2011 ;2011 Elsevier Ltd. All rights reserved. 2011 Elsevier Ltd ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(11)60739-3 ;PMID: 21663949 ;CODEN: LANCAO

Full text available

79
A decade of immune-checkpoint inhibitors in cancer therapy
Material Type:
Article
Add to My Research

A decade of immune-checkpoint inhibitors in cancer therapy

Nature communications, 2020-07, Vol.11 (1), p.3801-3801, Article 3801 [Peer Reviewed Journal]

The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Distributed under a Creative Commons Attribution 4.0 International License ;The Author(s) 2020 ;ISSN: 2041-1723 ;EISSN: 2041-1723 ;DOI: 10.1038/s41467-020-17670-y ;PMID: 32732879

Full text available

80
Publication Trends in Acupuncture Research: A 20-Year Bibliometric Analysis Based on PubMed
Material Type:
Article
Add to My Research

Publication Trends in Acupuncture Research: A 20-Year Bibliometric Analysis Based on PubMed

PloS one, 2016-12, Vol.11 (12), p.e0168123-e0168123 [Peer Reviewed Journal]

COPYRIGHT 2016 Public Library of Science ;COPYRIGHT 2016 Public Library of Science ;2016 Ma et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2016 Ma et al 2016 Ma et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0168123 ;PMID: 27973611

Full text available

Results 61 - 80 of 154,071  for All Library Resources

previous page 1 2 3 Results 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
  1. Before 1961  (112)
  2. 1961 To 1976  (181)
  3. 1977 To 1992  (1,919)
  4. 1993 To 2009  (17,693)
  5. After 2009  (134,348)
  6. More options open sub menu

Subject 

  1. Medical Research  (148,893)
  2. Science & Technology  (43,071)
  3. Life Sciences & Biomedicine  (32,742)
  4. Humans  (28,507)
  5. Oncology  (28,119)
  6. Tumors  (25,097)
  7. Patients  (18,364)
  8. Clinical Trials  (16,788)
  9. Medicine, Experimental  (14,860)
  10. Cancer Therapies  (14,415)
  11. Proteins  (13,512)
  12. Biotechnology Industry  (13,195)
  13. Female  (12,530)
  14. Care And Treatment  (11,925)
  15. Research & Development  (11,918)
  16. R&d  (11,917)
  17. Medicine  (11,483)
  18. Chemotherapy  (11,255)
  19. Immunotherapy  (10,975)
  20. More options open sub menu

Language 

  1. English  (153,724)
  2. Japanese  (6,581)
  3. French  (162)
  4. German  (136)
  5. Spanish  (124)
  6. Portuguese  (70)
  7. Norwegian  (49)
  8. Chinese  (39)
  9. Turkish  (30)
  10. Hindi  (21)
  11. Urdu  (6)
  12. Arabic  (6)
  13. Russian  (4)
  14. Dutch  (3)
  15. Hungarian  (2)
  16. Serbian  (2)
  17. Afrikaans  (2)
  18. Latin  (1)
  19. Italian  (1)
  20. Croatian  (1)
  21. More options open sub menu

Searching Remote Databases, Please Wait